Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization and is the new standard of care for this condition. Expand
Zolpidem: a review of its use in the management of insomnia.
In the only clinical trials that investigated the use of a hypnosedative drug in an 'as-needed' regimen, zolpidem produced a global improvement in sleep and remains a useful therapeutic option in the pharmacological treatment of patients with insomnia. Expand
Pioglitazone: a review of its use in type 2 diabetes mellitus.
In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles. Expand
Blonanserin: a review of its use in the management of schizophrenia.
Clinical data suggest that blonanserin is an effective and generally well tolerated option for the short-term treatment of schizophrenia and for those requiring longer-term therapy. Expand
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Once- or twice-daily atomoxetine was effective in the short-term treatment of ADHD in children and adolescents, as observed in several well designed placebo-controlled trials. Expand
Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation.
Intravenous dexmedetomidine provides a further option as a short-term (<24 hours) primary sedative in mechanically ventilated adult patients in an intensive care setting and in non-intubated adult patients prior to and/or during surgical and other procedures. Expand
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
- G. Keating
- 30 July 2010
In conclusion, rituximab remains a valuable therapy in patients with CLL, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma and, in a variety of treatment settings, represents the standard of care. Expand
Nalmefene: A Review of Its Use in the Treatment of Alcohol Dependence
- G. Keating
- CNS Drugs
- 16 August 2013
Oral nalmefene was generally well tolerated in patients with alcohol dependence, with the most commonly occurring adverse events including nausea, insomnia and dizziness, and provides an important new option for use in the treatment of alcohol dependence. Expand
Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Treatment with fenofibrate was associated with a significantly reduced risk of total cardiovascular disease (CVD) events, primarily through the prevention of non-fatal myocardial infarction and coronary revascularisation, and subgroup analyses revealed significant reductions in total CVD events and coronary heart disease events in patients with no previous CVD. Expand
Memantine: a review of its use in Alzheimer's disease.
In patients with mild to moderate Alzheimer's disease, data from three 24-week trials are equivocal, although meta-analyses indicate beneficial effects on global status and cognition, and Memantine is an effective pharmacotherapeutic agent, and currently the only approved option, for the treatment of moderate to severe Alzheimer's Disease. Expand